Healthcare stocks have faced challenges in recent years, but select companies still present compelling investment opportunities. Among them, Zoetis (ZTS) and BioNTech (BNTX) stand out as more attractive long-term options compared to Intellia Therapeutics (NTLA), which has shown volatility and uncertainty in its pipeline.

Zoetis, a leader in animal health, has encountered competition and scrutiny over its products but is positioned for recovery with new long-acting pain medications and a robust pipeline. Its dividend history, with a 458% increase over the past decade, makes it appealing for income-focused investors. Conversely, BioNTech’s struggles in the COVID-19 vaccine market have overshadowed its promising oncology pipeline, which includes over 25 clinical trials that could drive future growth.

Investors should consider Zoetis and BioNTech for their potential upside, while exercising caution with Intellia Therapeutics due to its high-risk profile and lengthy path to profitability.

Source: fool.com